Gabapentin Capsule
Product Images NDC 68071-3759

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-3759). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3759 1)

Label for Gabapentin 100 mg capsules from NuCare Pharmaceuticals, Inc. The label displays the product name, strength, dosage form, NDC number 68071-3759-1, and quantity of 100 capsules. It includes regulatory information, manufacturer address in Orange, CA, storage instructions, and warnings to keep out of reach of children.*

FDA Label Image

Equation (Equation)

An illustrated formula showing the calculation for creatinine clearance (CLCr). The equation includes variables for age, weight, serum creatinine, and a multiplier for female patients, representing how to estimate renal function.*

FDA Label Image

Fig 1 (Fig 1)

A line graph showing weekly mean pain scores over 8 weeks for placebo and gabapentin 3600 mg/day in an ITT population from Study 1. The graph includes baseline and two dose periods (1-week titration and 4-week fixed dose). Gabapentin shows a decreasing trend in pain scores compared to placebo over time.*

FDA Label Image

Fig 2 (Fig 2)

A line graph depicting weekly mean pain scores over seven weeks in an ITT population from Study 2. The graph compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day, showing mean pain scores from baseline through week 7, with a distinction between a 3-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Fig 3 (Fig 3)

A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies,' showing responder percentages for placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 compares PBO at 12% to GBP 3600 mg at 29%. Study 2 compares PBO at 14% to GBP 1800 mg at 32% and GBP 2400 mg at 34%. Statistical significance indicators are included.*

FDA Label Image

Fig 4 (Fig 4)

A bar chart illustrating the responder rate difference in percentage for patients receiving gabapentin compared to placebo, segmented by daily dose (600 mg to 1800 mg) and study (labeled as Study a, Study b, and Study c) in patients aged 12 years or older with partial seizures. The y-axis represents difference percentage, and the x-axis represents daily dose in milligrams.*

FDA Label Image

Structure (Struct)

Chemical structure of gabapentin showing a cyclohexane ring with side chains including an amino group and a carboxyl group. The diagram depicts the molecular structure of the active ingredient gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.